Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00845845 · ClinicalTrials.gov registry record · Phase 2
Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 study, sponsored by University of Illinois at Chicago.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00845845 is a Phase 2 study that was terminated before completion, run by University of Illinois at Chicago. The registered enrollment target is 12 participants.
The verdict
NCT00845845, a Phase 2 study, was terminated before completion, sponsored by University of Illinois at Chicago.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The current pilot study assesses the use of magnetic resonance imaging (MRI) to quantify hepatic steatosis. It will provide preliminary data regarding the use of omega-3 fatty acid supplementation (Lovaza) for the treatment of nonalcoholic steatohepatitis (NASH).
Interventions
- DRUG Placebo
- DRUG Omega-3-acid ethyl esters (Lovaza)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2006-03 |
| Est. Completion | 2010-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00845845
The ClinicalTrials.gov registry entry for NCT00845845 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00845845 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00845845 about?
NCT00845845 is a clinical study titled "Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)". The current pilot study assesses the use of magnetic resonance imaging (MRI) to quantify hepatic steatosis. It will provide preliminary data regarding the use of omega-3 fatty acid supplementation (Lovaza) for the treatment of nonalcoholic steatohepatitis (NASH).
What is the current status of trial NCT00845845?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2006-03. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00845845?
The interventions under investigation include: Placebo (DRUG), Omega-3-acid ethyl esters (Lovaza) (DRUG).
Who is sponsoring clinical trial NCT00845845?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.